Research Paper Volume 16, Issue 11 pp 10074—10107
Immunotherapy, prognostic, and tumor biomarker based on pancancer analysis, SMARCD3
Figure 6. Immunotherapy analysis of SMARCD3 in three cohorts. (A) Immunotherapy analysis of SMARCD3 in the GSE78220 cohort; (B) Immunotherapy analysis of SMARCD3 in the GSE67501 cohort; (C) Immunotherapy analysis of SMARCD3 in the IMvigor210 cohort. (D) Immunotherapy analysis of SMARCD3 in the GSE126044 cohort.